Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NA

BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the und

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven

MGK offers lower costs and mega-cap stability; SLYG delivered 27.4% returns over one year with broad

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when

Handelsbanken Fonder AB grew its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 28.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatri

FAS Wealth Partners Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by

Avidity Partners Management LP lifted its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT)

Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already re

Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overwei

Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance

Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prom

Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and

Dow Jones index gained 300 points, Lam Research Corp rose 20.1% after reporting strong financial res

Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:COR

Microsoft (NASDAQ: MSFT) reported strong Q4 results, beating revenue and earnings estimates. Shares

Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidanc

Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks C

Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% fro

Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio

Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $950.000 million-$1.050 billion

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.36 per share which beat the ana

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercia

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings p

Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perfo

Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announ

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86

On May 19, 2026, Corcept Therapeutics Incorporated (the "Company") learned that the United S

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and

Top Wall Street analysts changed outlook on top names. See all analyst rating changes, including upg

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:COR

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery

UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and rai

Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:COR

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweig

Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortf